S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
Morning sickness? Prenatal check-ups? What to know about new rights for pregnant workers
Tesla cuts US prices for 3 of its electric vehicle models after a difficult week
A coffee roastery in Finland has launched an AI-generated blend. The results were surprising
Autoworkers union celebrates breakthrough win in Tennessee and takes aim at more plants in the South
The House votes for possible TikTok ban in the US, but don't expect the app to go away anytime soon
Hawaii lawmakers take aim at vacation rentals after Lahaina wildfire amplifies Maui housing crisis
New York lawmakers pass $237 billion budget with policies to jump-start housing market
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
Morning sickness? Prenatal check-ups? What to know about new rights for pregnant workers
Tesla cuts US prices for 3 of its electric vehicle models after a difficult week
A coffee roastery in Finland has launched an AI-generated blend. The results were surprising
Autoworkers union celebrates breakthrough win in Tennessee and takes aim at more plants in the South
The House votes for possible TikTok ban in the US, but don't expect the app to go away anytime soon
Hawaii lawmakers take aim at vacation rentals after Lahaina wildfire amplifies Maui housing crisis
New York lawmakers pass $237 billion budget with policies to jump-start housing market
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
Morning sickness? Prenatal check-ups? What to know about new rights for pregnant workers
Tesla cuts US prices for 3 of its electric vehicle models after a difficult week
A coffee roastery in Finland has launched an AI-generated blend. The results were surprising
Autoworkers union celebrates breakthrough win in Tennessee and takes aim at more plants in the South
The House votes for possible TikTok ban in the US, but don't expect the app to go away anytime soon
Hawaii lawmakers take aim at vacation rentals after Lahaina wildfire amplifies Maui housing crisis
New York lawmakers pass $237 billion budget with policies to jump-start housing market
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
Morning sickness? Prenatal check-ups? What to know about new rights for pregnant workers
Tesla cuts US prices for 3 of its electric vehicle models after a difficult week
A coffee roastery in Finland has launched an AI-generated blend. The results were surprising
Autoworkers union celebrates breakthrough win in Tennessee and takes aim at more plants in the South
The House votes for possible TikTok ban in the US, but don't expect the app to go away anytime soon
Hawaii lawmakers take aim at vacation rentals after Lahaina wildfire amplifies Maui housing crisis
New York lawmakers pass $237 billion budget with policies to jump-start housing market
NASDAQ:IMAB

I-Mab (IMAB) Stock Price, News & Analysis

$1.80
0.00 (0.00%)
(As of 04/19/2024 ET)
Today's Range
$1.79
$1.85
50-Day Range
$1.57
$1.90
52-Week Range
$1.16
$3.45
Volume
335,382 shs
Average Volume
251,870 shs
Market Capitalization
$145.26 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$12.25

I-Mab MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
580.6% Upside
$12.25 Price Target
Short Interest
Healthy
1.45% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.48mentions of I-Mab in the last 14 days
Based on 2 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($1.97) to ($1.72) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.74 out of 5 stars

Medical Sector

411th out of 909 stocks

Pharmaceutical Preparations Industry

185th out of 427 stocks

IMAB stock logo

About I-Mab Stock (NASDAQ:IMAB)

I-Mab, a clinical stage biopharmaceutical company, discovers, develops, and commercializes biologics to treat cancer and autoimmune disorders. It is developing Felzartamab, a CD38 antibody that is in Phase 1b/2a for patients with membranous nephropathy; Eftansomatropin alfa, a long-acting growth hormone, which has completed Phase 3 clinical trials to treat pediatric growth hormone deficiency; Efineptakin alfa, a recombinant human IL-7 that is in Phase 2 for cancer treatment-related lymphopenia and cancer immunotherapy; and Lemzoparlimab, a CD47 monoclonal antibody that has completed Phase 2 clinical trial. Its product candidates also includes TJ210, a monoclonal antibody against human C5aR1 that is in Phase 1 for the treatment of cancers and autoimmune; Uliledlimab, a CD73 antibody, which is in Phase 2 clinical trials for treating solid tumors and oncology; TJ-L14B, a PD-L1-based tumor-dependent T-cell engager for solid cancers; Givastomig, a tumor-dependent T cell engager for gastric and other cancers; TJ-L1IF, a PD-L1/IFN-a antibody-cytokine fusion protein for PD(L)-1 resistant tumors; and TJ-C64B, a bispecific antibody for ovarian and other cancers. The company has strategic collaboration agreement with PT Kalbe Genexine Biologics; AbbVie Ireland Unlimited Company; Jumpcan Pharmaceutical Group; Sinopharm Group Co. Ltd.; and Roche Diagnostics. I-Mab was founded in 2014 and is headquartered in Shanghai, the People's Republic of China.

IMAB Stock Price History

IMAB Stock News Headlines

A.I. Pioneer Issues Urgent Warning to Americans
According to one early A.I. pioneer: “You can either use this as an unfair advantage to grow your wealth, or you can let it ravage your retirement savings. There’s no middle option.”
A.I. Pioneer Issues Urgent Warning to Americans
According to one early A.I. pioneer: “You can either use this as an unfair advantage to grow your wealth, or you can let it ravage your retirement savings. There’s no middle option.”
I-MAB Stock (NASDAQ:IMAB), Short Interest Report
I-Mab to Divest Chinese Unit for Up to $80M
I-Mab (IMAB) interactive stock chart – Yahoo Finance
I-Mab Announces Phase 1 Data of Givastomig at ESMO 2023
See More Headlines
Receive IMAB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for I-Mab and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Today
4/20/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:IMAB
Fax
N/A
Employees
228
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$12.25
High Stock Price Target
$25.00
Low Stock Price Target
$6.00
Potential Upside/Downside
+580.6%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
4 Analysts

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$3.89 million
Book Value
$2.93 per share

Miscellaneous

Free Float
62,867,000
Market Cap
$145.26 million
Optionable
Optionable
Beta
1.11
Investing Strategies To Help Grow Your Retirement Income Cover

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

Key Executives

  • Mr. Raj Kannan (Age 60)
    CEO & Director
  • Dr. Jerry Wang
    Co-Founder & Chief Scientific Officer
  • Mr. Skelton Joseph
    Chief Financial Officer
  • Mr. Tianyi Zhang
    Vice President of Investor Relations
  • Mr. Cheng Li (Age 40)
    Chief Legal Officer
  • Ms. Gigi Qi Feng (Age 43)
    Chief Communications Officer
  • Dr. Weiming Tang Ph.D. (Age 58)
    Executive VP of Global Business Development & Chief Business Officer
  • Dr. Fernando J. Salle´s Ph.D.
    Senior VP and Head of U.S. & EU Business Development
  • Claire Xu
    Head of US site
  • Dr. John Hayslip M.D. (Age 47)
    Chief Medical Officer

IMAB Stock Analysis - Frequently Asked Questions

Should I buy or sell I-Mab stock right now?

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for I-Mab in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" IMAB shares.
View IMAB analyst ratings
or view top-rated stocks.

What is I-Mab's stock price target for 2024?

4 Wall Street analysts have issued 1-year price objectives for I-Mab's stock. Their IMAB share price targets range from $6.00 to $25.00. On average, they anticipate the company's share price to reach $12.25 in the next twelve months. This suggests a possible upside of 580.6% from the stock's current price.
View analysts price targets for IMAB
or view top-rated stocks among Wall Street analysts.

How have IMAB shares performed in 2024?

I-Mab's stock was trading at $1.90 on January 1st, 2024. Since then, IMAB shares have decreased by 5.3% and is now trading at $1.80.
View the best growth stocks for 2024 here
.

Are investors shorting I-Mab?

I-Mab saw a increase in short interest in the month of March. As of March 31st, there was short interest totaling 1,170,000 shares, an increase of 7.3% from the March 15th total of 1,090,000 shares. Based on an average daily trading volume, of 436,300 shares, the days-to-cover ratio is presently 2.7 days.
View I-Mab's Short Interest
.

What other stocks do shareholders of I-Mab own?

Based on aggregate information from My MarketBeat watchlists, some companies that other I-Mab investors own include Inovio Pharmaceuticals (INO), Moderna (MRNA), ServiceNow (NOW), Novavax (NVAX), Gilead Sciences (GILD), Cisco Systems (CSCO), Enterprise Products Partners (EPD), G1 Therapeutics (GTHX), Intel (INTC) and Johnson & Johnson (JNJ).

When did I-Mab IPO?

I-Mab (IMAB) raised $100 million in an initial public offering (IPO) on Thursday, January 16th 2020. The company issued 7,400,000 shares at a price of $12.00-$15.00 per share. Jefferies and CICC acted as the underwriters for the IPO and China Renaissance and Huatai Securities (USA) were co-managers.

How do I buy shares of I-Mab?

Shares of IMAB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:IMAB) was last updated on 4/21/2024 by MarketBeat.com Staff

From Our Partners